Annals of internal medicine
-
Randomized Controlled Trial Multicenter Study
Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 × 2 Factorial Trial.
An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking. ⋯ The National Key R&D Program of China and the Project of Heilongjiang Province "TouYan" Innovation Team.
-
Randomized Controlled Trial
Time-Restricted Eating Without Calorie Counting for Weight Loss in a Racially Diverse Population : A Randomized Controlled Trial.
Time-restricted eating (TRE), without calorie counting, has become a popular weight loss strategy, yet long-term randomized trials evaluating its efficacy are limited. ⋯ National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
-
Comment Randomized Controlled Trial Multicenter Study
In ischemic stroke, adding EVT to usual care at 6 to 24 h improved functional status at 90 d.
Olthuis SGH, Pirson FAV, Pinckaers FME, et al; MR CLEAN-LATE investigators. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet. 2023;401:1371-1380. 37003289.
-
Randomized Controlled Trial
Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly : A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial.
Daily low-dose aspirin increases major bleeding; however, few studies have investigated its effect on iron deficiency and anemia. ⋯ National Institutes of Health and Australian National Health and Medical Research Council.
-
Comment Randomized Controlled Trial
In ACS with multivessel CAD, immediate vs. staged complete revascularization was noninferior for a composite outcome at 1 y.
Diletti R, den Dekker WK, Bennett J, et al; BIOVASC Investigators. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401:1172-1182. 36889333.